Anumana Announces Collaboration with Novartis for AI-ECG Solutions

See Release

Anumana in the News

Divider
All Topics
Recent

Media Contact | info@anumana.net

Medical Xpress

Migraine with aura identified as independent risk factor for A-fib

Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online June 8 in Headache. The study used Mayo Clinic developed algorithm for detecting atrial fibrillation, which is now licensed to Anumana.

August 3, 2022

MedCity News

Novartis turns to algorithms developer Anumana to apply AI to cardio conditions

Novartis is partnering with algorithms startup Anumana to develop a new artificial intelligence-based solution for cardiovascular diseases. The goal is to find ways to detect heart conditions years before symptoms develop in order to enable earlier intervention.

July 14, 2022

PharmaShots

Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease

The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease. The AI will screen for atherosclerotic CV disease which can cause a heart attack or stroke. An evidence-based, digital point-of-care system will be created in order to improve medical therapies & lower the risk of hospitalizations and CV death

July 13, 2022

Medical Device Network

Anumana partners with Novartis for AI-driven heart disease detection

Health technology company Anumana and Novartis Pharmaceuticals Corporation have entered a partnership to use artificial intelligence (AI) for the detection of heart diseases. Under the multi-year collaboration, the companies will seek to deploy multiple AI-powered software solutions that will be able to identify hidden cardiovascular conditions.

July 13, 2022

AI Tech Park

Anumana Collaborates with Novartis Pharmaceuticals Corporation

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence (AI)-powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.

July 13, 2022

of 12

Partner with us!

We’re actively developing algorithms for FDA approval. Please direct partnership and media inquiries to info@anumana.net